Pharma channel feed

DBV lays off em­ploy­ees, scales down pro­grams af­ter re­ceiv­ing no word from FDA

5 years ago
FDA+

Sanofi preps an­oth­er round of lay­offs as new ex­ecs look to slim down the glob­al phar­ma in an on­go­ing re­or­ga­ni­za­tion — re­port

5 years ago

Af­ter 2 de­lays, Zo­genix nabs FDA ap­proval for epilep­sy drug, sets price at 3X its GW Phar­ma com­peti­tor

5 years ago
FDA+

UK Supreme Court strikes down Re­gen­eron patents, open­ing door for Kymab

5 years ago

What's the hard cost of a piv­otal drug tri­al? A lot less than you might ex­pect

5 years ago

Epizyme hits the ground run­ning with sec­ond — and cru­cial — OK for Tazverik, in fol­lic­u­lar lym­phoma

5 years ago
FDA+

Hours af­ter block­buster patent win, My­lan asks the FDA to speed up an OK to mar­ket a gener­ic to Bio­gen’s Tec­fidera

5 years ago
FDA+

In a fresh blow, Bio­gen los­es a big court fight with My­lan over its block­buster Tec­fidera patent

5 years ago

Ab­b­Vie-Al­ler­gan com­plete, but crit­ics con­tin­ue to raise an­ti-com­pet­i­tive con­cerns

5 years ago
Deals

Mer­ck eats the lunch Bris­tol My­ers nev­er served, win­ning TMB-based OK for Keytru­da

5 years ago

As­traZeneca spin­off scores maid­en FDA ap­proval, where it will field Alex­ion com­pe­ti­tion and an im­mi­nent Roche ri­val

5 years ago
R&D
FDA+

At­tor­neys gen­er­al bring an­oth­er ‘col­lu­sion’ case against gener­ic mak­ers, nam­ing No­var­tis and Pfiz­er among over a dozen oth­ers

5 years ago

Ab­b­Vie’s patent-ag­gres­sive US strat­e­gy for flag­ship Hu­mi­ra pays off, as judge dis­miss­es law­suit al­leg­ing an­ti­com­pet­i­tive ac­tiv­i­ty

5 years ago

GSK presents case to ex­pand use of its lu­pus drug in pa­tients with kid­ney dis­ease, but the field is evolv­ing. How long will the mo­nop­oly last?

5 years ago
R&D

Es­ti­mat­ing a US price tag of $5K per course, remde­sivir is set to make bil­lions for Gilead, says key an­a­lyst

5 years ago
R&D
Coronavirus

A low-pro­file biotech bests Re­gen­eron in high-pro­file patent suit

5 years ago

Pfiz­er, Mer­ck KGaA ce­ment Baven­cio blad­der can­cer win with OS da­ta — while carv­ing an­oth­er niche in rare can­cer

5 years ago
R&D

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

5 years ago
People

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based op­tion

5 years ago
FDA+

Ger­man Mer­ck bests US Mer­ck in UK copy­right tus­sle of Mer­ck v. Mer­ck

5 years ago

FDA ap­proves the first gener­ic for Amar­in's Vas­cepa — but is a fish oil price war im­mi­nent?

5 years ago
FDA+

Parkin­son's pa­tients no longer need to re­ly on a nee­dle for apo­mor­phine an­ti­dote for 'of­f' episodes af­ter new FDA ap­proval

5 years ago
FDA+

Once val­ued at $4B, an em­bat­tled Ako­rn — nurs­ing a mar­ket cap of rough­ly $37M — files for bank­rupt­cy

5 years ago
FDA+

As­traZeneca, Mer­ck push block­buster fran­chise to an­oth­er key FDA ap­proval, rel­e­gat­ing a ri­val to sec­ond-fid­dle sta­tus

5 years ago
FDA+
First page Previous page 253254255256257258259 Next page Last page
A service from the Financial Times